Regarding the increasing enthusiasm for lung cancer immunotherapy and our hypothesis, we next assessed and compared the TME landscape between the MIP and LEP components using the stepwise activities of the cancer immunity cycle. The gene discussed is MIP; the disease is lung carcinoma.